New hope for advanced stomach cancer: targeted drug combo trial launches
NCT ID NCT06630130
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests whether combining targeted therapies (Trastuzumab Deruxtecan and Capecitabine, with or without Rilvegostomig) before and after surgery can help people with a certain type of advanced stomach cancer (HER2-positive) that cannot be removed right away. About 50 adults will take part. The goal is to see if the treatment shrinks the tumor enough for surgery and to check safety and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.